Objectives To determinate the correlation between serum anti-dsDNA titer and Systemic Lupus Erythematosus Disease Activity

Introduction Lupus is a chronic autoimmune inflammatory disease which affects more women with a peak in incidence of reproductive age. Serological tests are used to determine the activity of the disease and predict the precipitation of the disease. Anti ds-DNA antibodies are found in high levels, on patients serum with LES flare, but not in normal person serum and in patients with other autoimmune disease such as discoid lupus erythematosus, chronic hepatitis or rheumatoid arthritis. Usually during the activation of the disease we have a decrease of complement and increase of anti ds-DNA.

Methods The patients included in the study are 42, with an average age of 25–35 years and with the highest percentage of patients being female (40 females and 2 males). The double stand ds-DNA antibody serum was measured. The disease activity was evaluated by SLEDAI evaluation. The SLEDAI is a global index that was developed and introduced in 1985 as a clinical index for the assessment of lupus disease activity in the preceding 10 days. It consists of 24 weighted clinical and laboratory variables of nine organ systems.

Results The growth of anti-ds DNA was observed in all patients with a flare of disease. Positive correlation was observed between SLEDAI and anti-dsDNA levels. It was observed that this correlation was significant between the anti-ds-DNA titer and the SLEDAI activity r = 0.52 (p <0.0001).

Conclusion The implementation of SLEDAI is a clinically important tool for evaluating patients with LES. Serial measurement of anti-ds DNA can help us diagnose lupus flare and make the right therapeutic decision for patients with SLEDAI high points.